Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if GERN is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
44 top institutions tracked
Last 13F trend: distributing (light)
Unlock crowding heatmapUnlock filer discoverySentiment: unknown
No recent insider trades detected.
Red flags: 5
258 filers reported a long position in GERN for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| BlackRock, Inc. | $62.9M | 49.1M | +3.8% |
| RA CAPITAL MANAGEMENT, L.P. | $54.8M | 42.8M | -32.9% |
| Soleus Capital Management, L.P. | $54.8M | 42.8M | +3.1% |
| STATE STREET CORP | $45.9M | 35.9M | +17.6% |
| CITADEL ADVISORS LLC | $37.2M | 29M | +34.6% |
| VANGUARD CAPITAL MANAGEMENT LLC | $34.9M | 27.3M | +2.2% |
| Clearbridge Investments, LLC | $25.2M | 19.6M | +0.1% |
| Eversept Partners, LP | $24M | 18.7M | -0.6% |
| GOLDMAN SACHS GROUP INC | $21.3M | 16.6M | +48.8% |
| GEODE CAPITAL MANAGEMENT, LLC | $18.6M | 14.6M | +6.5% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.